Sensitivity of primary R5 HIV-1 to inhibition by RANTES correlates with sensitivity to small-molecule R5 inhibitors

Antiviral Therapy

Volumn 10, Issue 2, 2005, Pages 231-237

  Koning, Fransje A ^a   Koevoets, Cindy ^a   Van Der Vorst, Teun J K ^a   Schuitemaker, Hanneke ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4 [1 [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4 METHYL 4 PIPERIDINYL] 2 METHYL 1 [1 [4 (TRIFLUOOROMETHYL)PHENYL]ETHYL]PIPERAZINE; ANTIGEN P24; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; RANTES; UNCLASSIFIED DRUG; ZIDOVUDINE; HETEROCYCLIC COMPOUND;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS ISOLATION; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PHYSIOLOGY; VIROLOGY; VIRUS REPLICATION;

DOSE-RESPONSE RELATIONSHIP, DRUG; HETEROCYCLIC COMPOUNDS; HIV INFECTIONS; HIV-1; HUMANS; MALE; RANTES; RECEPTORS, CCR5; VIRUS REPLICATION;

EID: 22844443584     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM & Berger EA. CC CKR5: A RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272:1955-1958.
2. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M, Collman RG & Doms RW. A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3 and CKR-2b as fusion cofactors. Cell 1996; 85:1149-1158.
3. + cell depletion and progression to AIDS. Annals of Internal Medicine 1993; 118:681-688.
4. De Roda Husman AM, van Rij RP, Blaak H, Broersen S & Schuitemaker H. Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for HIV-1 disease progression. Journal of Infectious Diseases 1999; 180:1106-1115.
5. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC & Lusso P. Identification of RANTES, MIP-1α and MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270:1811-1815.
6. Raport CJ, Gosling J, Schweickart VL, Gray PW & Charo IF. Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1β and MIP-1α. Journal of Biological Chemistry 1996; 271:17161-17166.
7. Mackewicz CE, Barker E & Levy JA. Role of β-chemokines in suppressing HIV replication. Science 1996; 274:1393-1394.
8. Paxton WA, Martin SR, Tse D, O'Brien TR, Skurnick J, Vandevanter NL, Padian N, Braun JF, Kotler DP, Wolinsky SM & Koup RA. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures. Nature Medicine 1996; 2:412-417.
9. + lymphocytes from exposed-uninfected individuals: association with low expression of CCR5 and high production of β-chemokines. Virology 1998; 244:66-73.
10. Garzino-Demo A, Moss RB, Margolick JB, Cleghorn F, Sill A, Blattner WA, Cocchi F, Carlo DJ, DeVico AL & Gallo RC. Spontaneous and antigen-induced production of HIV-inhibitory β-chemokines are associated with AIDS-free status. Proceedings of the National Academy of Sciences, USA 1999; 96:11986-11991.
11. Saha K, Bentsman G, Chess L & Volsky DJ. Endogenous production of β-chemokines by CD4+, but not CD8+ T-cell clones correlates with the clinical state of human immunodeficiency virus type 1 (HIV-1)-infected individuals and may be responsible for blocking infection with non-syncytium-inducing HIV-1 in vitro. Journal of Virology 1998; 72:876-881.
12. Koning FA, Kwa D, Boeser-Nunnink B, Dekker J, Vingerhoed J, Hiemstra H & Schuitemaker H. Decreasing sensitivity to RANTES neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection. Journal of Infectious Diseases 2003; 188:864-872.
13. Stalmeijer EH, van Rij RP, Boeser-Nunnink B, Visser JA, Naarding MA, Schols D & Schuitemaker H. In vivo evolution of X4 human immunodeficiency virus type 1 variants in the natural course of infection coincides with decreasing sensitivity to CXCR4 antagonists. Journal of Virology 2004; 78:2722-2728.
14. Schols D. HIV co-receptors as targets for antiviral therapy. Current Topics in Medicinal Chemistry 2004; 4:883-893.
15. Strizki JM, Xu S, Wagner NE, Wojcik L, Liu J, Hou Y, Endres M, Palani A, Shapiro S, Clader JW, Greenlee WJ, Tagat JR, McCombie S, Cox K, Fawzi AB, Chou C-C, Pugliese-Sievo C, Davies L, Moreno ME, Ho DD, Trkola A, Stoddart CA, Moore JP, Reyes GR & Baroudy BM. SCH-C (SCH 351125), an orally bioavailable, small molecule antagnoist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proceedings of the National Academy of Sciences, USA 2001; 98:12718-12723.
16. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, Shiraishi M, Aramaki Y, Okonogi K, Ogawa Y, Meguro K & Fujino M. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proceedings of the National Academy of Sciences, USA 1999; 96:5698-5703.
17. O'Connell MA, Belanger MA & Haaland PD. Calibration and assay development using four-parameter logistic model. Chemometrics & Intelligent Laboratory Systems 1993; 20:97-114.
18. Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, Morgan T, Pugach P, Xu S, Wojcik L, Tagat J, Palani A, Shapiro S, Clader JW, McCombie S, Reyes GR, Baroudy BM & Moore JP. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proceedings of the National Academy of Sciences, USA 2002; 99:395-400.
19. Dragic T, Trkola A, Thompson DA, Cormier EG, Kajumo FA, Maxwell E, Lin SW, Ying W, Smith SO, Sakmar TP & Moore JP. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proceedings of the National Academy of Sciences, USA 2000; 97:5639-5644.
20. Tsamis F, Gavrilov S, Kajumo F, Seibert C, Kuhmann S, Ketas T, Trkola A, Palani A, Clader JW, Tagat JR, McCombie S, Baroudy B, Moore JP, Sakmar TP & Dragic T. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. Journal of Virology 2003; 77:5201-5208.
21. Karlsson I, Antonsson L, Shi Y, Karlsson A, Albert J, Leitner T, Olde B, Owman C & Fenyo EM. HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. AIDS 2003; 17:2561-2569.